Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

NCT01797965 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01797965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01797965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
February 15, 2013
Completion date
September 24, 2018
Enrollment
1,501 (actual)
Sites
222

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing-remitting multiple sclerosis